Risk Stratification-directed Therapy for AML With t(8;21) /AML1-ETO+

NACompletedINTERVENTIONAL
Enrollment

207

Participants

Timeline

Start Date

October 31, 2016

Primary Completion Date

December 31, 2021

Study Completion Date

December 31, 2022

Conditions
Acute Myeloid LeukemiaRisk Stratification
Interventions
OTHER

Consolidation with chemotherapy (CT) or autologous hematopoietic stem cell transplantation (auto-HSCT)

"For CT, patients were treated with high dose cytarabine (HDAC), cytarabine at a dosage of 1-3 g/m2 q12 h ×6 doses, for 4-6 cycles.~For auto-HSCT, patients were treated with 3 cycles of HDAC and then bridged to auto-HSCT."

OTHER

Consolidation with auto-HSCT or HLA-matched HSCT

"For auto-HSCT, patients were treated with 3 cycles of HDAC and then bridged to auto-HSCT.~For HLA-matched HSCT, patients were treated with 1-2 cycles of HDAC and then bridged to HLA-matched HSCT. HLA-matched donors were available in these patients."

OTHER

allogeneic HSCT

For allogeneic HSCT, patients were treated with 1-2 cycles of HDAC and then bridged to allogeneic HSCT, including HLA-matched and haploidentical transplantation.

All Listed Sponsors
collaborator

Zhujiang Hospital

OTHER

lead

Nanfang Hospital, Southern Medical University

OTHER

NCT02936089 - Risk Stratification-directed Therapy for AML With t(8;21) /AML1-ETO+ | Biotech Hunter | Biotech Hunter